LGL Group (NYSEAMERICAN:LGL) Announces Earnings Results

LGL Group (NYSEAMERICAN:LGL) announced its quarterly earnings data on Monday. The industrial products company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.07 by ($0.09), reports. LGL Group had a net margin of 16.50% and a return on equity of 1.66%. The business had revenue of $0.80 million during the quarter, compared to analysts’ expectations of $9.10 million.

LGL Group Price Performance

Shares of LGL stock traded up $0.15 during trading hours on Wednesday, hitting $7.10. The stock had a trading volume of 3,233 shares, compared to its average volume of 12,477. The stock has a market capitalization of $46.35 million, a price-to-earnings ratio of 63.55 and a beta of 0.31. LGL Group has a one year low of $5.45 and a one year high of $9.74. The stock’s 50-day moving average price is $7.14 and its two-hundred day moving average price is $6.48.

Institutional Inflows and Outflows

An institutional investor recently raised its position in LGL Group stock. Osaic Holdings Inc. boosted its holdings in shares of LGL Group, Inc. (The) (NYSEAMERICAN:LGL) by 15.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,250 shares of the industrial products company’s stock after purchasing an additional 2,710 shares during the quarter. Osaic Holdings Inc. owned about 0.38% of LGL Group worth $154,000 as of its most recent SEC filing. 30.28% of the stock is currently owned by institutional investors and hedge funds.

About LGL Group

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.